Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No special consideration for Rocket J. squirrel though
K,
I also read Keytruda imho, and therefore LL is pointing to a combo that may achieve a most important first, but hey I’m not a doctor nor do I play one on TV
So I took it as Dcvax may prolong life with minimal side effects = quality of life,
But Dcvax + CI May cure
Both cases have tremendous merit in my non-expert opinion, and if born out portend value in Dcvax and nwbo.
Did I answer your question?
Remember LL’s slide said vaccine + CI = tumors killed
I think CI is checkpoint inhibitor but I might be misremembering.
When you’re here long enough, and you haven’t been through the deep so drop a lot of us have, then complain or since you’re apparently short term oriented, you can cash out your chips and play another horse.
I live and let live usually however you’re giving off some negative vibes towards the posters here, like using all caps often and quickness to complain and such.
It’s not that you’re posting doubts because we have longstanding fudsters here that we exchange with with decorum and even humor.
Maybe it’s me having a bad day in general or maybe longtime longs who have been through much worse sp movement than in a very long time.
What I remember is that the mesynchimal (sp?) subtype of GBM seems to do better with dcvax despite being the relatively worse prognosis. I think the more mixed the tumor is, the more targets for the dcvax enhanced immune response. The methylation and IHG types also factor in, if memory serves me.
Jerry I’m increasingly appreciating your ability and knowledge to cut through all the noise and point out the clear and available information such as for this filing delay, and other recent subjects of speculation. Two thumbs up!
Thanks Flip, I worked under an IP agreement for about 40 years (retired now) and attend multiple tutorials about the patent process however I do not remember anyone mentioning the 18 month interval but that was likely not among the main points the tutorials were meant to make.
Thank you very much!
Yep, keeping my fingers crossed!
As in let’s take a Cruise where martinis are shaken, not stirred.
WRT nwbo, I have resolved myself to just settle down and wait for the TLD to be announced. I do believe it will be soon, not 2021, but I’m also the one who was sure it was to be announced by SNO. Needless to say I was humbled.
Discretion is the better part of valor! Thank you for sparing me what is best unspoken
Could it be a double agent? (Drummer plays rim shot)
I had a hosted business dinner in Seoul, South Korea about 20 years ago, and we ate what was brought out to us and it was all good. The one ground rule request we made of our host was please no dog. I know we had ox tail but the rest was anonymous. Truth be told, by the time we were halfway through the endless customary rounds of scotch whiskey rounds, we were feeling no pain and open to new culinary experiences
Flip,
If I’m interpreting correctly, this patent was applied for in 2016 and awarded in February 2019?
Timing then suggests the science is exhibited in 2015-2016 results?
Also I only saw MB as inventor. Does patent belong to nwbo per MB being employed by nwbo?
Your thoughts?
TIA
I took the further step of moving my nwbo shares in my traditional IRA to my Roth IRA recently, figuring better to take the conversion tax hit now with the stock price between $1.25 - $1.60 than when it hopefully increases by multiples of the current level. It would have been better sub-dollar but the significant tax savings are in the future.
Of course if the stock collapses then I lose my investment and have to pay the taxes due from the conversion as well, but I’m optimistic!
Also indicates that trial patients know the limitations of current SOC and thus if not trying the new treatment then no hope of doing significantly better.
Seeing my moms battle and trying different therapies including one that was made available under a trial, she endured progressively more debilitating side effects for the hope of achieving at least a suspension of progression. She didn’t have GBM but rather started as primary bladder cancer in her kidney.
I’m still questioning my judgement of when I stopped advising her to try the last couple of drugs with serious side effects and minimal life extension if the side effects didn’t kill you suddenly at any time. Had there been some real hope I would have advised to continue trying.
So for GBM, if you don’t get benefit early enough you may be out of runway much earlier than for other cancers, therefore the need for real hope and the morality of not designing a GBM trial that doesn’t provide a crossover at a minimum.
My mom passed last Thanksgiving morning and particularly on my mind today. Please no need for sympathy as you’ve all already expressed them the previous times I’ve posted about my mom, and I thank you all again.
Amen and hallelujah !
Doc Logic,
Thanks for your thorough and considered reply. I could live with either scenario and yours would be a very positive outcome!
Is the following hypothetical scenario beyond the realm of possibility?
Perlmutter recently retired, yes?
He lead Merck’s oncology products research and hired back his keytruda applications lead from a short stint at nwbo around the time the SAP was believed to be finished.
LP and Perlmutter were face to face at an oncology conference prior to the hire of the keytruda lead by nwbo.
Would it be possible that Perlmutter be enticed out of retirement to become CEO of nwbo, with LP as Chairman of the Board and large shareholder, with potential partnerships or buyout a little down the road?
Just throwing this out for opinions while we continue waiting for TLD.
They just accomplished an 80+ site phase 3 across four countries (not even accounting for othe EU nations) and one SAP and revised endpoints.
Yea what a bunch of slothes, not!
I kinda miss Scotty...... Naaahhhhh!!!
Absolutely good points.
In the extreme I guess life itself comes with the risk (indeed, certainty) of death (and of course taxes.)
Did you call me?
I came up with my ID thinking Dcvax might be the “horse” that sets up the immune system to enhance the CarT combo efficacy.
Just a intuitive guess and I wanted an ID I would remember.
It’s funny how each individual perceives their own message, which we all are entitled to have.
I perceive the second article as more of an update with the latest info and views.
I continue to view the articles as positive and everyone must acknowledge the possibilities of failure as well as success.
Absolutely a lot of big hair, and the women tended to have big hair too
Wow! What a small world! The bagel place was on 86th between Gelston and 5th avenues.
I just looked at a map and on the corner of Gelston and 86th there is a long building that runs lengthwise down Gelston, that is probably where the bar was. It’s a Tiger Shulman’s martial arts now.
Sorry to the board for being off topic. I couldn’t help being nostalgic.
Regarding nwbo, I’ll take these slow and steady increases in sp until TLD is released. GLTA!
Not that you can get this anymore, but when I was late teens with my friends we would drive to the bagel place on 86th street near the Verrazano bridge in Brooklyn and get them fresh hot around 1am and continue cruising in our cars.
Yes this was a little before Saturday Night Fever and that night club actually did exist in that area.
Disco, disco duck!
Bagel counts as a full meal if it’s got a shmear of cream cheese and some smoked salmon
Skitahoe,
Yes I think if one pieces together the various tidbits from across presentations, one gets a sense of markers for better prospects for response to the dcvax-l treatment.
I think the markers include: mesynchimal (so?), methylated and IDH Wild, parameters.
Also, how much tumor burden remains at start of dcvax treatment, since it’s been mentioned that the lower the amount of gbm tumor the greater the chance of dcvax providing significant benefits.
Si Fabio, Io sono Marco Polo
Solo un scerzo. Buona fortuna!
Btw, there were a few people on the LL Galbraith teleconference from nvcr
I also call BS!!!
The trial was completed and the data locked, period!
The statisticians are analyzing the data per LL.
There will be unblinding once the statisticians are done.
How long the company and SAB and LL hold on before unblinding the public is somewhat indeterminate, however I would think there would be pressure to unblind the public and move along to the next steps of filing for approval.
That’s a glass half empty view.
The glass half full view is that DCVax-L becomes SOC for GBM, and if the dcvax/keytruda combo eliminates tumors that would be absolutely great!
The details around total costs would be workable by definition to make the treatment available to those that need it. Similarly the FUD around dcvax not being part of the combo treatment is also just FUD IMO.
This possible combo is the most compelling factor in possibly making a Merck-NWBO partnership or merger plausible, and even if kept separate, the two products would be used in combination if the combo works!
Surely you jest!
I know, my name’s not Sherly
Yes, the next steps after DL were given by nwbo in the PR and did indicate PI being unblinded along with the company and being part of the process of assessing the results package. Also I don’t think LL would participate in any plot but rather just continue to pursue the science.
Does that mean all the statisticians keep throwing data balls at a wall and waiting for one to go through
Need to verify with others since the same person can post multiple venues
She would be unblinded among the first I would think.
The meeting host booted us